Literature DB >> 21449228

Heparin-induced thrombocytopenia and extracorporeal membrane oxygenation: a case report and review of the literature.

Uri Pollak1, Joanne Yacobobich, Hannah Tamary, Ovdi Dagan, Orit Manor-Shulman.   

Abstract

Heparin-induced thrombocytopenia (HIT) is an immune-mediated coagulation side effect of heparin therapy characterized by thrombocytopenia and by a paradoxical prothrombotic state following heparin exposure when thrombotic or thromboembolic events accurse, the condition is classified as Heparin-induced thrombocytopenia with thrombosis (HITT). We report a case of HITT with evidence of small-vessel arterial thrombosis in a 5-day-old newborn receiving extracorporeal membrane oxygenation (ECMO) for congenital diaphragmatic hernia, and our attempt of bivalirudin alternative treatment. We also review previous reports regarding HIT and ECMO with the alternative management in this unique population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21449228      PMCID: PMC4680089     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  45 in total

Review 1.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

Review 2.  Heparin-induced thrombocytopenia: towards consensus.

Authors:  T E Warkentin; B H Chong; A Greinacher
Journal:  Thromb Haemost       Date:  1998-01       Impact factor: 5.249

3.  A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT).

Authors:  W Jy; W W Mao; L L Horstman; P A Valant; Y S Ahn
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

Review 4.  New approaches to the diagnosis of heparin-induced thrombocytopenia.

Authors:  Theodore E Warkentin
Journal:  Chest       Date:  2005-02       Impact factor: 9.410

Review 5.  Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.

Authors:  Thomas L Ortel
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

6.  Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia.

Authors:  Karim Jabr; Joe H Johnson; Miles H McDonald; Diane L Walsh; William D Martin; Anton C Johnson; John M Pickett; Usha Shantha-Martin
Journal:  J Extra Corpor Technol       Date:  2004-06

Review 7.  Drugs for the prevention and treatment of thrombosis in patients with heparin-induced thrombocytopenia.

Authors:  N Lubenow; A Greinacher
Journal:  Am J Cardiovasc Drugs       Date:  2001       Impact factor: 3.571

Review 8.  Heparin-induced thrombocytopenia.

Authors:  A Greinacher
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

9.  Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporeal life support.

Authors:  Katherine E Potter; Ashok Raj; Janice E Sullivan
Journal:  J Pediatr Hematol Oncol       Date:  2007-04       Impact factor: 1.289

10.  Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation.

Authors:  William E Dager; Robert C Gosselin; Richard Yoshikawa; John T Owings
Journal:  Ann Pharmacother       Date:  2004-02-24       Impact factor: 3.154

View more
  11 in total

1.  Acute oxygenator failure: a new presentation of heparin-induced thrombocytopenia in a patient undergoing venovenous extracorporeal membrane oxygenation support.

Authors:  Robert A Ratzlaff; Juan G Ripoll; Lena L Kassab; Jose L Diaz-Gomez
Journal:  BMJ Case Rep       Date:  2016-12-16

Review 2.  Principles and indications of extracorporeal life support in general thoracic surgery.

Authors:  Karen McRae; Marc de Perrot
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

Review 3.  Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.

Authors:  Marcia L Buck
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Nov-Dec

4.  Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation.

Authors:  Marco Ranucci; Andrea Ballotta; Hassan Kandil; Giuseppe Isgrò; Concetta Carlucci; Ekaterina Baryshnikova; Valeria Pistuddi
Journal:  Crit Care       Date:  2011-11-20       Impact factor: 9.097

5.  Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients.

Authors:  Marco Ranucci; Ekaterina Baryshnikova; Giuseppe Isgrò; Concetta Carlucci; Mauro Cotza; Giovanni Carboni; Andrea Ballotta
Journal:  Crit Care       Date:  2014-09-05       Impact factor: 9.097

6.  Perioperative care in an adolescent patient with heparin-induced thrombocytopenia for placement of a cardiac assist device and heart transplantation: case report and literature review.

Authors:  Mineto Kamata; Roby Sebastian; Patrick I McConnell; Daniel Gomez; Aymen Naguib; Joseph D Tobias
Journal:  Int Med Case Rep J       Date:  2017-02-14

7.  Acute renal failure due to bilateral renal vein thromboses: A rare complication of heparin-induced thrombocytopenia.

Authors:  Allan M Klompas; Robert C Albright; Simon Maltais; Onur Demirci
Journal:  Ann Card Anaesth       Date:  2019 Apr-Jun

8.  Use of argatroban for extracorporeal life support in patients with nonheparin-induced thrombocytopenia: Analysis of 10 consecutive patients.

Authors:  Young Su Kim; Heemoon Lee; Ji-Hyuk Yang; Kiick Sung; Gee Young Suh; Chi Ryang Chung; Jeong Hoon Yang; Yang Hyun Cho
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

Review 9.  Anticoagulation in Neonatal ECMO: An Enigma Despite a Lot of Effort!

Authors:  Katherine Cashen; Kathleen Meert; Heidi Dalton
Journal:  Front Pediatr       Date:  2019-09-13       Impact factor: 3.418

Review 10.  Hematologic concerns in extracorporeal membrane oxygenation.

Authors:  Jonathan Sniderman; Paul Monagle; Gail M Annich; Graeme MacLaren
Journal:  Res Pract Thromb Haemost       Date:  2020-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.